keyword
MENU ▼
Read by QxMD icon Read
search

HPV vaccines safety

keyword
https://www.readbyqxmd.com/read/28328521/human-papillomavirus-first-and-second-generation-vaccines-current-status-and-future-directions
#1
Somayeh Pouyanfard, Martin Müller
It has been more than 10 years that the first prophylactic papillomavirus vaccine became available, although distribution has been mainly limited to the more affluent countries. The first two vaccines have been a great success, hundreds of millions of women and a much smaller number of men have been vaccinated ever since. In a few countries with high vaccination coverage, in particular Australia but also parts of Great Britain and others, clinical impact of vaccination programs is already visible and there are indications for herd immunity as well...
March 22, 2017: Biological Chemistry
https://www.readbyqxmd.com/read/28319456/reactogenicity-of-cervarix-and-gardasil-human-papillomavirus-hpv-vaccines-in-a-randomized-single-blind-trial-in-healthy-uk-adolescent-females
#2
Tao Haskins-Coulter, Jo Southern, Nick Andrews, Elizabeth Miller
One hundred and ninety eight females aged 12-15 y were enrolled in an observer-blinded randomized trial to assess the immunogenicity and reactogenicity of the tetravalent HPV vaccine Gardasil® (group 2), in comparison to the bivalent HPV vaccine, Cervarix® (group 1), which was routinely offered in the national vaccination schedule at the time. Participants were blinded to treatment group until all 3 vaccinations had been given, while laboratory staff were masked during testing. For the majority of local and general reactions, recipients of both vaccines reported comparable frequencies...
March 20, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28266092/six-year-multi-centre-observational-post-marketing-surveillance-of-the-safety-of-the-hpv-16-18-as04-adjuvanted-vaccine-in-women-aged-10-25%C3%A2-years-in-korea
#3
Chul-Jung Kim, Rok Song, Jing Chen, Fernanda Taveres Da Silva, Kusuma B Gopala, Joon Hyung Kim, Dan Bi, Jong Sup Park
PURPOSE: To evaluate the safety of HPV-16/18 AS04-adjuvanted vaccine when administered as per the PI in Korea. METHODS: A total of 3084 women aged 10-25 years were enrolled in this post-marketing surveillance from 2008 to 2014. Subjects were invited to receive three doses of the vaccine (0, 1 and 6 months), and participants who received at least one dose were included in the analysis. Adverse events (AEs), adverse drug reactions (ADRs) and serious AEs (SAEs) were recorded after each dose...
March 7, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28193249/factors-associated-with-parental-reasons-for-no-intent-to-vaccinate-female-adolescents-with-human-papillomavirus-vaccine-national-immunization-survey-teen-2008-2012
#4
Vinay K Cheruvu, Madhav P Bhatta, Lauren N Drinkard
BACKGROUND: 1) To identify socio-demographic factors associated with parental "no-intent" for their 13-17 year old unvaccinated daughter to receive the human papillomavirus (HPV) vaccine series within the next twelve months, 2) to describe patterns in "no-intent" by socio-demographic factors, and 3) to identify socio-demographic factors associated with parental reasons for "no-intent". METHODS: Data from 2008-2012 National Immunization Survey - Teen (NIS - Teen) were examined in this study...
February 13, 2017: BMC Pediatrics
https://www.readbyqxmd.com/read/28190705/risk-of-autoimmune-diseases-and-human-papilloma-virus-hpv-vaccines-six-years-of-case-referent-surveillance
#5
Lamiae Grimaldi-Bensouda, Michel Rossignol, Isabelle Koné-Paut, Alain Krivitzky, Christine Lebrun-Frenay, Johanna Clet, David Brassat, Caroline Papeix, Marc Nicolino, Pierre-Yves Benhamou, Olivier Fain, Nathalie Costedoat-Chalumeau, Marie-France Courcoux, Jean-François Viallard, Bertrand Godeau, Thomas Papo, Patrick Vermersch, Isabelle Bourgault-Villada, Gerard Breart, Lucien Abenhaim
BACKGROUND: Safety of HPV vaccines is still in question due to reports of autoimmune diseases (ADs) following HPV immunization. OBJECTIVES: To assess the risk of ADs associated with HPV vaccination of female adolescents/young adults in France. METHODS: Systematic prospective case-referent study conducted to assess the risks associated with real-life use of HPV vaccines. Cases were female 11-25 years old with incident ADs [central demyelination/multiple sclerosis (CD/MS), connective tissue disease (CTD), Guillain-Barré syndrome (GBS), type-1 diabetes (T1D), autoimmune thyroiditis (AT), and idiopathic thrombocytopenic purpura (ITP)]...
February 9, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28153042/pragmatic-trial-of-an-intervention-to-increase-human-papillomavirus-vaccination-in-safety-net-clinics
#6
Maureen Sanderson, Juan R Canedo, Dineo Khabele, Mary K Fadden, Cynthia Harris, Katina Beard, Marilyn Burress, Helen Pinkerton, Cynthia Jackson, Tilicia Mayo-Gamble, Margaret K Hargreaves, Pamela C Hull
BACKGROUND: Human papillomavirus (HPV) infection has been causally linked to six cancers, and many disproportionately affect minorties. This study reports on the development and effectiveness of an intervention aimed at increasing HPV vaccine uptake among African American and Hispanic pediatric patients in safety-net clinics. METHODS: Formative research, community engagement, and theory guided development of the intervention. A clustered, non-randomized controlled pragmatic trial was conducted in four clinics providing healthcare for the underserved in Tennessee, U...
February 2, 2017: BMC Public Health
https://www.readbyqxmd.com/read/28087890/overview-of-the-benefits-and-potential-issues-of-the-nonavalent-hpv-vaccine
#7
REVIEW
Luciano Mariani, Mario Preti, Paolo Cristoforoni, Carlo M Stigliano, Antonio Perino
HPV-related diseases affect anogenital and oropharyngeal regions, heavily affecting the psychosexual dimension of both male and female individuals. HPV vaccination programs based on a bivalent or quadrivalent vaccine have opened broad perspectives for primary prevention. A nonavalent HPV vaccine (9vHPV), covering nine genotypes (HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9vHPV vaccine development programs are examined...
December 7, 2016: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/28073618/characteristics-of-adolescents-lacking-provider-recommended-human-papillomavirus-vaccination
#8
Melinda Krakow, Anna Beavis, Olivia Cosides, Anne F Rositch
PURPOSE: To characterize subgroups of teens in the United States for whom provider recommendation is less likely to impact human papillomavirus (HPV) vaccine initiation. METHODS: We analyzed provider-verified vaccination data from the Centers for Disease Control and Prevention's 2014 National Immunization Survey-Teen. Poisson regression models identified characteristics associated with the lack of HPV vaccine initiation among teens who received a provider recommendation (n = 12,742)...
January 7, 2017: Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine
https://www.readbyqxmd.com/read/28073220/what-do-we-know-about-the-safety-of-the-hpv-vaccines
#9
Peter C Gøtzsche
No abstract text is available yet for this article.
January 2017: Tidsskrift for Den Norske Lægeforening: Tidsskrift for Praktisk Medicin, Ny Række
https://www.readbyqxmd.com/read/28053505/spotlight-on-the-9-valent-hpv-vaccine
#10
REVIEW
Pier Luigi Lopalco
Starting in 2006, vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries. Two vaccines have been successfully used, a bivalent vaccine targeting HPV-related cancers (bHPV) and a quadrivalent vaccine (qHPV) targeting both HPV-related cancers and genital warts. Between December 2014 and June 2015, a new nonavalent HPV vaccine (9vHPV) was granted marketing authorization in the USA and Europe. The 9vHPV was developed from the qHPV and includes five additional HPV types that should increase the level of protection toward HPV-related cancers...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28042137/immunogenicity-and-safety-of-human-papillomavirus-hpv-vaccination-in-asian-populations-from-six-countries-a-meta-analysis
#11
Didik Setiawan, Jos Luttjeboer, Koen B Pouwels, Jan C Wilschut, Maarten J Postma
Cervical cancer is a serious public-health problem in Asian countries. Since human papillomavirus (HPV) infection is the main risk factor for cervical cancer, HPV vaccination is considered a promising strategy to prevent cervical cancer. However, comprehensive immunogenicity and safety information for Asian populations is lacking. We searched four electronic databases including PubMed, EMBASE, Cochrane Library, and clinicaltrials.gov. We reviewed selected manuscripts and extracted the pooled relative risk (RR) from immunogenicity and safety information on HPV vaccination among women in Asian countries...
January 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28003597/safety-and-immunogenicity-study-of-a-9-valent-human-papillomavirus-vaccine-administered-to-9-to-15-year-old-japanese-girls
#12
Satoshi Iwata, Shinya Murata, Shi Rong Han, Akira Wakana, Miyuki Sawata, Yoshiyuki Tanaka
A 9-valent human papillomavirus (HPV 6/11/16/18/31/33/45/52/58) virus-like particle (VLP) vaccine (9vHPV) has been proven highly efficacious in preventing anogenital disease related with vaccine HPV types in a pivotal Phase III study in women aged 16 to 26 years. We report here the results of an open-label phase III study conducted to bridge the findings in women age 16 to 26 years to Japanese girls aged 9 to 15 years. All subjects (n = 100) received a 3-dose regimen of 9vHPV vaccine at day 1, month 2 and month 6...
December 22, 2016: Japanese Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27998015/efficacy-immunogenicity-and-safety-of-the-hpv-16-18-as04-adjuvanted-vaccine-in-chinese-women-aged-18-25%C3%A2-years-event-triggered-analysis-of-a-randomized-controlled-trial
#13
Feng-Cai Zhu, Shang-Ying Hu, Ying Hong, Yue-Mei Hu, Xun Zhang, Yi-Ju Zhang, Qin-Jing Pan, Wen-Hua Zhang, Fang-Hui Zhao, Cheng-Fu Zhang, Xiaoping Yang, Jia-Xi Yu, Jiahong Zhu, Yejiang Zhu, Feng Chen, Qian Zhang, Hong Wang, Changrong Wang, Jun Bi, Shiyin Xue, Lingling Shen, Yan-Shu Zhang, Yunkun He, Haiwen Tang, Naveen Karkada, Pemmaraju Suryakiran, Dan Bi, Frank Struyf
We previously reported the results of a phase II/III, double-blind, randomized controlled study in Chinese women (NCT00779766) showing a 94.2% (95% confidence interval: 62.7-99.9) HPV-16/18 AS04-adjuvanted vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 1 or higher (CIN1+) and/or 6-month (M) persistent infection (PI) with a mean follow-up of <2 years, and immunogenicity until 7 months post-dose 1. Here, we report efficacy and safety results from an event-triggered analysis with ~3 years longer follow-up, and immunogenicity until M24...
January 2017: Cancer Medicine
https://www.readbyqxmd.com/read/27940751/achieving-high-adolescent-hpv-vaccination-coverage
#14
Anna-Lisa M Farmar, Kathryn Love-Osborne, Katherine Chichester, Kristin Breslin, Kristi Bronkan, Simon J Hambidge
BACKGROUND AND OBJECTIVE: Despite national recommendations for adolescent human papillomavirus (HPV) vaccination, rates have lagged behind those of other adolescent vaccines. We implemented interventions and examined rates of vaccination coverage in a large, urban, safety net health care system to understand whether our tactics for achieving high rates of adolescent vaccination were successful. METHODS: Denver Health is an integrated urban safety net health system serving >17 000 adolescents annually...
November 2016: Pediatrics
https://www.readbyqxmd.com/read/27934795/current-global-status-impact-of-human-papillomavirus-vaccination-implications-for-india
#15
REVIEW
Rengaswamy Sankaranarayanan, Neerja Bhatla, Partha Basu
This review addresses the effectiveness and safety of human papillomavirus (HPV) vaccines, the current status of its introduction in the National Immunization Programmes (NIPs) and its relevance to India, which contributes a fifth of the global burden of cervical cancer. The vast literature on efficacy, acceptability and safety of HPV vaccination and its impact after population level introduction was reviewed and discussed. The efficacy of HPV vaccines in preventing high-grade precancerous lesions caused by vaccine-targeted HPV infections was 90 per cent or higher in HPV naοve women in randomized clinical trials...
August 2016: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/27912928/translating-self-persuasion-into-an-adolescent-hpv-vaccine-promotion-intervention-for-parents-attending-safety-net-clinics
#16
Austin S Baldwin, Deanna C Denman, Margarita Sala, Emily G Marks, L Aubree Shay, Sobha Fuller, Donna Persaud, Simon Craddock Lee, Celette Sugg Skinner, Deborah J Wiebe, Jasmin A Tiro
OBJECTIVE: Self-persuasion is an effective behavior change strategy, but has not been translated for low-income, less educated, uninsured populations attending safety-net clinics or to promote human papillomavirus (HPV) vaccination. We developed a tablet-based application (in English and Spanish) to elicit parental self-persuasion for adolescent HPV vaccination and evaluated its feasibility in a safety-net population. METHODS: Parents (N=45) of age-eligible adolescents used the self-persuasion application...
November 20, 2016: Patient Education and Counseling
https://www.readbyqxmd.com/read/27910798/a-qualitative-study-of-women-who-experience-side-effects-from-human-papillomavirus-vaccination
#17
Tina Sørensen, Pernille Tanggaard Andersen
INTRODUCTION: In Denmark, vaccination against human papillomavirus (HPV) is offered to girls and women to prevent cervical cancer. Unfortunately, reporting of possible side effects from vaccination has increased in recent years. Therefore, the present study examine women's experiences of side effects from the HPV vaccine. METHODS: In-depth qualitative interviews were conducted with eight HPV-vaccinated Danish women, aged 25-44 years, who experienced side effects from the vaccine...
December 2016: Danish Medical Journal
https://www.readbyqxmd.com/read/27895921/literature-review-of-vaccine-related-adverse-events-reported-from-hpv-vaccination-in-randomized-controlled-trials
#18
Mohamed Macki, Ali A Dabaja
BACKGROUND: The human papilloma virus (HPV) infections were addressed with two FDA-approved HPV vaccines: quadrivalent and bivalent vaccine. The objective of this manuscript is to determine the safety of the HPV vaccine. RESULTS: A search of PubMed articles for "human papillomavirus vaccine" was used to identify all-type HPV clinical studies prior to October 2014. A refined search of clinical trials, multicenter studies, and randomized studies were screened for only randomized controlled trials comparing HPV vaccine to controls (saline placebo or aluminum derivatives)...
2016: Basic and Clinical Andrology
https://www.readbyqxmd.com/read/27864489/protecting-women-against-human-papillomavirus-benefits-barriers-and-evidence-based-strategies-to-increase-vaccine-uptake
#19
Tamera Coyne-Beasley, Bridget E Hochwalt
Human papillomavirus (HPV) infection significantly impacts women, as it can cause cancers and precancers of the cervix, vulva, vagina, oropharynx, and anus. However, many of these cancers can be prevented by HPV vaccination. Despite evidence of vaccine effectiveness and safety, vaccination rates remain low. Evidence-based strategies should be utilized to reduce barriers and increase vaccination rates.
November 2016: North Carolina Medical Journal
https://www.readbyqxmd.com/read/27858522/hpv-vaccine-related-knowledge-beliefs-acceptability-and-uptake-among-latinas-who-prefer-english-and-those-who-prefer-spanish
#20
Kimlin Tam Ashing, Noé Rubén Chávez, Mayra Serrano
Latinas compose almost 10% of the U.S. population and suffer the highest incidence of and one of the highest mortality rates from cervical cancer. Human papillomavirus (HPV) vaccination can prevent most HPV infections that cause more than 90% of cervical cancer. Unfortunately, limited knowledge and low rates of HPV vaccination persist among Latinas. The current study compared awareness, knowledge, beliefs, acceptability, uptake, and 3-dose series completion of HPV vaccination between Latinas who prefer English (EPL) and those who prefer Spanish (SPL), ages 18-62, living in Southern California...
December 2016: Journal of Health Communication
keyword
keyword
102610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"